Amphastar Updates Executive Employment Agreements to Strengthen Leadership

Amphastar Pharmaceuticals ( (AMPH) ) just unveiled an update.

On March 3, 2026, Amphastar Pharmaceuticals entered into new executive employment agreements with board member and Executive Vice President of Corporate Administration Center Jacob Liawatidewi and Senior Executive Vice President of Production Center Rong Zhou, setting one-year renewable terms and clarifying at-will termination rights. The contracts establish base salaries of $525,800 for Liawatidewi and $590,000 for Zhou, performance-based bonuses, equity eligibility, and comprehensive severance protections, including double-salary cash payouts, extended health benefits, and accelerated equity vesting upon qualifying terminations or change in control events, underscoring Amphastar’s emphasis on executive retention and stability in its leadership ranks.

If either executive is terminated without cause, not renewed, or resigns for good reason, they become eligible for significant lump-sum severance, continued insurance premiums for up to 12 months, and full vesting of unvested equity awards, with enhanced benefits if such termination occurs around a change in control. The agreements also provide prorated and accrued bonus payments upon certain terminations and include tax-efficient treatment of potential parachute payments, potentially increasing costs but aligning incentives and providing clearer protections for senior management and other stakeholders in the event of corporate transitions or strategic transactions.

The most recent analyst rating on (AMPH) stock is a Hold with a $21.00 price target. To see the full list of analyst forecasts on Amphastar Pharmaceuticals stock, see the AMPH Stock Forecast page.

Spark’s Take on AMPH Stock

According to Spark, TipRanks’ AI Analyst, AMPH is a Neutral.

The score is primarily driven by mixed fundamentals: strong historical margins/returns and low reported leverage, but a sharp TTM revenue/margin reset and very weak/uncertain TTM cash-flow support. Technicals are a significant drag with a clear downtrend and weak momentum. Offsetting these risks, valuation looks inexpensive (P/E ~9.95) and the latest call supports a cautiously positive outlook for 2026 growth driven by new launches and key brands, though margin pressure remains a notable headwind.

To see Spark’s full report on AMPH stock, click here.

More about Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceuticals company focused on developing, manufacturing, and marketing injectable, inhalation, and intranasal products, as well as other pharmaceutical formulations. The company operates in the broader healthcare and life sciences sector, targeting hospital, clinical, and retail markets for its therapeutic offerings.

Average Trading Volume: 418,421

Technical Sentiment Signal: Sell

Current Market Cap: $927.4M

For a thorough assessment of AMPH stock, go to TipRanks’ Stock Analysis page.